Literature DB >> 9383684

Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity.

R J van't Hof1, S H Ralston.   

Abstract

Interferon-gamma (IFN-gamma) has been shown to inhibit interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha) stimulated bone resorption by strongly stimulating nitric oxide (NO) synthesis. Here we studied the mechanisms underlying this inhibition. Osteoclasts were generated in 10-day cocultures of mouse osteoblasts and bone marrow cells and the effect of cytokine-induced NO on osteoclast formation and activity was determined. Stimulation of the cocultures with IL-1 beta, TNF-alpha and IFN-gamma markedly enhanced NO production by 50- to 70-fold, and this was found to be derived predominantly from the osteoblast cell layer. When high levels of NO were induced by cytokines during early stages of the cocultures, osteoclast formation was virtually abolished and bone resorption markedly inhibited. Cytokine stimulation during the latter stages of coculture also resulted in inhibition of bone resorption, but here the effects were mainly due to an inhibitory effect on osteoclast activity. At all stages, however, the inhibitory effects of cytokines on osteoclast formation and activity were blocked by the NO-synthase inhibitor L-NMMA. Further investigations suggested that the NO-mediated inhibition of osteoclast formation was due in part to apoptosis of osteoclast progenitors. Cytokine stimulation during the early stage of the culture caused a large increase in apoptosis of bone marrow cells, and these effects were blocked by L-NMMA and enhanced by NO donors. We found no evidence of apoptosis in osteoclasts exposed to high levels of cytokine-induced NO at any stage in the culture, however, or of apoptosis affecting mature osteoclasts exposed to high levels of NO, suggesting that immature cells in the bone marrow compartment are most sensitive to NO-induced apoptosis. In summary, these studies identify NO as a potentially important osteoblast-osteoclast coupling factor which has potent inhibitory effects on bone resorption. These actions, in turn, are mediated by inhibition of osteoclast formation probably due to NO-induced apoptosis of osteoclast progenitors and by inhibition of the resorptive activity of mature osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9383684     DOI: 10.1359/jbmr.1997.12.11.1797

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  31 in total

Review 1.  Nitric oxide and bone.

Authors:  R J van't Hof; S H Ralston
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

3.  Bone marrow blood vessel ossification and "microvascular dead space" in rat and human long bone.

Authors:  Rhonda D Prisby
Journal:  Bone       Date:  2014-03-27       Impact factor: 4.398

4.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.

Authors:  Yuhao Gao; Francesco Grassi; Michaela Robbie Ryan; Masakazu Terauchi; Karen Page; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

5.  The role of nitric oxide in the mechanical repression of RANKL in bone stromal cells.

Authors:  Jill Rahnert; Xian Fan; Natasha Case; Tamara C Murphy; Francesco Grassi; Buer Sen; Janet Rubin
Journal:  Bone       Date:  2008-03-20       Impact factor: 4.398

6.  iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats.

Authors:  Bruno S Herrera; Rodrigo Martins-Porto; Aline Maia-Dantas; Paula Campi; Luis C Spolidorio; Soraia K P Costa; Thomas E Van Dyke; Robert Gyurko; Marcelo N Muscara
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

Review 7.  The Oxygen Paradox, the French Paradox, and age-related diseases.

Authors:  Joanna M S Davies; Josiane Cillard; Bertrand Friguet; Enrique Cadenas; Jean Cadet; Rachael Cayce; Andrew Fishmann; David Liao; Anne-Laure Bulteau; Frédéric Derbré; Amélie Rébillard; Steven Burstein; Etienne Hirsch; Robert A Kloner; Michael Jakowec; Giselle Petzinger; Delphine Sauce; Florian Sennlaub; Isabelle Limon; Fulvio Ursini; Matilde Maiorino; Christina Economides; Christian J Pike; Pinchas Cohen; Anne Negre Salvayre; Matthew R Halliday; Adam J Lundquist; Nicolaus A Jakowec; Fatima Mechta-Grigoriou; Mathias Mericskay; Jean Mariani; Zhenlin Li; David Huang; Ellsworth Grant; Henry J Forman; Caleb E Finch; Patrick Y Sun; Laura C D Pomatto; Onnik Agbulut; David Warburton; Christian Neri; Mustapha Rouis; Pierre Cillard; Jacqueline Capeau; Jean Rosenbaum; Kelvin J A Davies
Journal:  Geroscience       Date:  2017-12-21       Impact factor: 7.713

8.  Idiopathic hypercalciuria: O2(-)NO relationship and altered bone metabolism.

Authors:  L Calò; S Giannini; P Bonvicini; M Nobile; S Cantaro; M Plebani; A Semplicini; A D'Angelo; G Crepaldi
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

9.  Interaction of Brucella abortus with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and Vaccine Safety.

Authors:  Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Larry J Suva; Dana Gaddy; Angela M Arenas-Gamboa
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

10.  TRAP-positive osteoclast precursors mediate ROS/NO-dependent bactericidal activity via TLR4.

Authors:  Kazuaki Nishimura; Satoru Shindo; Alexandru Movila; Rayyan Kayal; Albassam Abdullah; Irma Josefina Savitri; Atsushi Ikeda; Tsuguno Yamaguchi; Mohammed Howait; Ayman Al-Dharrab; Abdulghani Mira; Xiaozhe Han; Toshihisa Kawai
Journal:  Free Radic Biol Med       Date:  2016-06-22       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.